Home
- Eating Well (or at Least Not terribly) at Fast Food Resturants
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Insulin Articles
Popular Insulin Articles
Highly Recommended Insulin Articles
Email to a Friend
Send a link to this page to your friends and colleagues.
Insulin Analog Levemir Lowers BG Levels in 60 Percent of Type 2 Patients
Levemir is Novo’s brand name for insulin detemir, a long-acting manmade insulin analog that acts up to 24 hours to maintain healthy BG levels.
Novo Nordisk has announced that results from a study show that almost 60 percent of type 2 patients taking once-daily doses of its Levemir insulin analog were able to reach the average blood sugar level recommended by the American Diabetes Association.
(Levemir is Novo's brand name for insulin detemir, a long-acting manmade insulin analog that acts up to 24 hours to maintain healthy BG levels.)
The study, called TITRATE, involved 244 type 2 diabetes patients who were on oral anti-diabetes drugs and had never before used insulin. They were assigned to one of two treatment groups with different goals as their fasting blood sugar targets: 70 to 90 mg/dl (an A1c of 4% to 4.7%) or 80 to 110 mg/dl (an A1c of 4.4% to 5.4%). The patients continued their use of oral diabetes drugs and learned how to change their Levemir doses every three days in order to close in on their target A1c levels.
The patients had a starting A1c of less than 9%. In the group with the 70 to 90 mg/dl target, 64.3 percent of patients were able to reach the ADA-recommended A1c of less than 7% in 20 weeks. In the 80 to 110 mg/dl target group, 54.5 percent of patients reached the same goal. The overall drop in A1c for the first group was 1.2%, to an average of 6.77%. The second group saw its average A1c drop 0.9% to 7%.
The study found that the rate of minor hypoglycemic events was 5.09 events/patient/year in the 70 to 90 mg/dl target group and 3.16 events/patient/year in the 80 to 110 mg/dl target group. One patient in the 70 to 90 mg/dl group experienced a major hypoglycemic event requiring third party assistance.
The TITRATE study was published online in the journal Diabetes, Obesity & Metabolism.
Categories: A1c Test, Blood Sugar, Diabetes, Diabetes, Insulin, Novo Nordisk, Type 2 Issues
You May Also Be Interested In...
-
Diabetes Health
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
-
Topics
- Diabetic / Diabetes Health
- Type 1 / 1.5 Diabetes
- Type 2 Diabetes
- Blood Glucose / Sugar
- High/Low Blood Sugar / Fast Acting Glucose
- Insulin- Pumps, Pens & Syringes
- Continuous Glucose Monitors, CGM, Infusion Sets
- Type 2 Medications
- Hyperglycemia
- Hypoglycemia
Comments
This study is really not news, it is corporate promotional propaganda for Novo Nordisk. A better study would have compared Levemir to Lantus, not oral meds. There have been such studies, although the rate of improvement is not nearly as noteworthy as 60%.
I switched to levemir from UL, after two unsuccessful trials, with lantus. I find levemir excellent at controlling morning bg numbers. As I am also on humalog as a bolus, and no orals, this is the most important thing a basal insulin can do for me. I was diagnosed with type 2 diabetes in 1983, my control is good with Alc levels below six.
Why are you giving A1cs after the fasting levels? Those A1cs are for the *average* BG, not the fasting levels. You can have a fasting level of 70 and go very high after meals and stay high a long time and have a high A1c.
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...